This market research report on the global drug-coated balloons market offers analysis on market size & forecast, market share, industry trends, growth drivers, and vendor analysis. The market study also includes insights on segmentation by indication (DCB for peripheral artery disease, DCB for coronary artery disease, and DCB for other indications), by end-user (hospitals, cardiac catheterization labs, and ASCs), and by geography (North America, Europe, APAC, and ROW).
The increasing prevalence and incidences of cardiovascular devices, especially PAD and CAD is driving the growth of the global drug-coated balloons market. The growing awareness about vascular diseases and the increasing availability of various endovascular and cardiovascular treatment options will boost the demand in the worldwide market. The interventional procedures with DCBs are associated with fewer complications, higher success rates, and a faster recovery rate than other techniques that are available in the market. The government agencies and leading vendors are taking various steps to raise awareness among patients and the general public. This technique is a rapidly growing category of medical devices that combines the biological effect of a drug and mechanical dilatation of a balloon catheter to treat occluded arteries. The numerous benefits of these devices over existing treatment options for treating arterial diseases is leading to the development of the global market. The establishment of lucrative reimbursement policies will drive the demand for these systems in the global market over the next few years. The high incidence of vascular diseases due to an unhealthy lifestyle, aging population, rising demand for MI angioplasty procedures, technological advancements, and increasing awareness among patients are of the primary factors contributing to the adoption of this technology. The introduction of DCBs has a significant breakthrough in the cardiovascular industry and with its enormous potential regarding minimizing restenosis. The benefits of this procedure are likely to become a new standard for treating cardiovascular diseases in the global drug-coated balloons market.
The gradual shift towards MI surgical techniques will help vendors to launch new products. These procedures are highly accurate, less painful, have faster recovery time, minimal complications, cause fewer post-surgery related infections, less blood loss, and reduce hospital stay of patients, which will contribute to the growth of the market. The global drug-coated balloons market is expected to reach revenues of more than $1 billion by 2024, growing at a CAGR of around 17% during 2018-2024.
The rising availability of clinical data and growing focus on clinical trials is contributing to the revenues in the global drug-coated balloons market. The vendors are focusing on conducting clinical trials to generate abundant clinical evidence regarding the safety and efficacy of these medical devices in the global market. The positive clinical trials will change the dynamics and create lucrative opportunities for leading vendors operating in the global market. The regulatory bodies are introducing various new guidelines to fasten the approval process of these procedures. These guidelines allow vendors to collect data on product safety and efficacy before finalization of device design while still adhering to patient safety during clinical trials. Such initiatives will improve the safety of these devices and promote the development of the market during the forecast period. For instance, B. Braun Melsungen’sSeQuent Please NEO had shown outstanding safety and efficacy profile in more than 20 clinical studies/registries in the market. The availability of latest and positive clinical evidence will boost the adoption in the global drug-coated balloons market.
This market research report includes a detailed segmentation of the market by indication, end-users, and geography.
Drug-Coated Balloons Market – By Indication
The advances in endovascular therapy are propelling the growth of the DCBs for PAD in the global drug-coated balloons market
The global drug-coated balloons market by indication is classified into DCB for peripheral artery disease, DCB for coronary artery disease, and DCB for other indications. DCB for peripheral artery disease segment dominated the majority of total market share in 2018, growing at a CAGR of over more than 16% during the forecast period. The increasing advancements in endovascular therapy are propelling the growth of this segment in the global market. This procedure has offered a significant breakthrough and completely changed the treatment landscape of PAD, especially femoropopliteal artery disease. This medical procedure also helps reduce high restenosis and revascularization rates like other therapies available in the global market. The sure of these devices are less expensive than stenting procedures, especially in situations where multiple stents are needed for treating longer lesions. The increasing adoption of these medical devices across developed nations will propel the growth of the global drug-coated balloons market.
DCB catheters deliver an anti-proliferative drug to the target arterial, as well as prevent restenosis without the need for additional implants like stents; their usage has expanded in treating coronary artery lesions in the market. The growing popularity of this procedure for an endovascular treatment option for stenotic AVF and AVG in patients undergoing hemodialysis will contribute to the growth of the global drug-coated balloons market.
Drug-coated Balloons Market – By End-Users
Cost-effectiveness of ASCs is driving the demand for these services in the global drug-coated balloons market
The end-user segment in the global drug-coated balloons market is categorized into hospitals, cardiac catheterization labs, and ASCs. ASCs is the fastest growing end-user segment in the global market, at a CAGR of over 19% during the forecast period. The growing shift from open cardiovascular surgical techniques toward MI and percutaneous-based procedures especially across developed countries is contributing to the growth of the ASC segment in the global market. The technological advancements in interventional procedures, increasing demand for less invasive surgeries, and high growth in the development of out-patient services are some of the factors attributing to the rising demand for ASCs in the global market. The cost-effectiveness and the quality of patient care with the minimum indirect cost of treatment will attribute to the growing revenues in this market segment. The ASCs provide advanced operating equipment, specialist surgeons, and well-equipped operating and recovery rooms without the complex administrative procedures that burden most hospitals. The increasing focus on reducing healthcare expenditure will propel the growth of this segment in the global drug-coated balloons market.
The innovations and demand for advanced catheter-based cardiovascular and endovascular procedures across countries such as the US, Germany, France, and Japan will boost the demand for hospitals in the market. The growing prevalence of co-morbidities, such as diabetes and obesity will lead to the requirement of cardiac catheterization labs and drive the growth of the global drug-coated balloons market.
Drug-coated Balloons Market – By Geography
Technological innovations across North America will drive the evolution of the global drug-coated balloons market
The global drug-coated balloons market by geography is segmented into North America, Europe, APAC, and ROW. North America occupied more than half of the total market share in 2018, growing at a CAGR of more than 18% during the forecast period. The growing prevalence of various cardiovascular risk factors, such as high BP, smoking, lack of physical activity, obesity, and diabetes are the main factors boosting the adoption of these procedures in the North American market. The availability of advanced healthcare infrastructure, constant technological innovations, and growing acceptance for advanced MI endovascular devices will create lucrative opportunities for leading vendors operating in the North American market. The players are investing in the development of innovative and advanced products that offer improved results using MI surgical techniques in the market. The North American region is witnessing commercialization of DCBs, new product approvals, and availability of abundant clinical evidence, which will positively impact the global drug-coated balloons market over the next few years.
The availability of a broad range of medical devices for treating various vascular indications across Europe is contributing to the revenues in the market. The increasing awareness among people about various CVDs and their treatment options to decrease the mortality rate and comorbidity in the APAC region will drive the global drug-coated balloons market.
The key countries profiled in the report are:
Key Vendor Analysis
The global drug-coated balloons market is highly dynamic due to the presence of international, regional, and local players. The top companies are focusing on wide geographical reach, diversified product portfolio, and a strong focus on innovation and research activities to attract a maximum of consumers in the global market. The emerging companies to expand their presence, enhance product portfolio, and improve expertise to sustain the competition in the market. The increase in M&A activities will drive consolidation in the global drug-coated balloons market.
The major vendors in the global market are:
Other prominent vendors include Boston Scientific, Opto Circuits (India), Acotec Scientific, AR Baltic Medical, Acrostak, Biosensors International Group, Cardionovum, Endocor, iVascular SLU, Minvasys, QT Vascular, BioMed , SurModics, Concept Medical, Hexacath Sverige, RD Global-Invamed, MedAlliance, Terumo, and Wellinq.
Key market insights include
Get the updated report free if published within 100 days of purchase
Free datasheet worth $1500 with team and corporate license.
10% free customization. Speak to our analyst